New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
09:02 EDTBDSI, ENDPBioDelivery Sciences could be bought by Endo, says Summer Street
Summer Street sees shares of BioDelivery Sciences (BDSI) heading to the $15 level on positive buprenorphine data in July, a drug the company partners with Endo (ENDP). The firm notes Endo could owe up to $70M in milestones to BioDelivery, but it finds it more likely that Endo buys BioDelivery outright. Summer Street keeps a Buy rating on the stock with a $20 price target.
News For BDSI;ENDP From The Last 14 Days
Check below for free stories on BDSI;ENDP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
10:02 EDTENDPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:42 EDTENDPEndo initiated with an Outperform at RBC Capital
Subscribe for More Information
August 25, 2014
09:26 EDTENDPEndo puts AMS medical-device unit up for sale, WSJ says
Subscribe for More Information
August 22, 2014
09:38 EDTBDSIBioDelivery Sciences sales may jump on DEA move, says Summer Street
Subscribe for More Information
August 19, 2014
07:34 EDTBDSIBioDelivery Sciences management to meet with William Blair
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use